Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy

References

• Li Z, Lai X, Fu S, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci. 2022;9(22):e2201734. doi:10.1002/advs.202201734
   Web of Science ®Google Scholar
• Estapé Senti M, García Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond. Adv Drug Deliv Rev. 2024;206:115190. doi:10.1016/j.addr.2024.115190
   PubMed Web of Science ®Google Scholar
• Leonard WJ, Lin JX. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 2023;22(10):827–854. doi:10.1038/s41573-023-00746-x
   PubMed Web of Science ®Google Scholar
• Liu Y, Adu-Berchie K, Brockman JM, et al. Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A. 2023;120(1):e2213222120. doi:10.1073/pnas.2213222120
   PubMedGoogle Scholar
• Shojaie L, Bogdanov JM, Alavifard H, et al. Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis. 2024;15(2):140. doi:10.1038/s41419-024-06535-7
   PubMed Web of Science ®Google Scholar
• Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 2017;25(8):1163–1174. doi:10.1016/j.str.2017.06.011
   PubMed Web of Science ®Google Scholar
• Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509–528. doi:10.1038/s41573-021-00345-8
   PubMed Web of Science ®Google Scholar
• Niu C, Zhu K, Zhang J, et al. Analysis of immune-related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors. Int, J, Cancer. 2024;154(7):1261–1271. doi:10.1002/ijc.34813
   PubMed Web of Science ®Google Scholar
• Desai J, Fong P, Moreno V, et al. A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. Br J Cancer. 2023;128(8):1418–1428. doi:10.1038/s41416-022-02128-3
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. doi:10.1186/s12943-019-1091-2
   PubMed Web of Science ®Google Scholar
• Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed Engl. 2019;58(3):670–680. doi:10.1002/anie.201804882
   PubMed Web of Science ®Google Scholar
• Kang X, Zhang Y, Song J, et al. A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy. Nat Commun. 2023;14(1):5216. doi:10.1038/s41467-023-40996-2
   PubMed Web of Science ®Google Scholar
• Wang L, Geng H, Liu Y, et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm. 2023;4(5):e343. doi:10.1002/mco2.343
   PubMedGoogle Scholar
• Giustarini G, Pavesi A, Adriani G. Nanoparticle-based therapies for turning cold tumors hot: how to treat an immunosuppressive tumor microenvironment. Front Bioeng Biotechnol. 2021;9:689245. doi:10.3389/fbioe.2021.689245
   PubMed Web of Science ®Google Scholar
• Mao L, Ma P, Luo X, et al. Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy. ACS Nano. 2023;17(11):9826–9849. doi:10.1021/acsnano.3c02273
   PubMed Web of Science ®Google Scholar
• Cui L, Wang X, Liu Z, et al. Metal-organic framework decorated with glycyrrhetinic acid conjugated chitosan as a pH-responsive nanocarrier for targeted drug delivery. Int J Biol Macromol. 2023;240:124370. doi:10.1016/j.ijbiomac.2023.124370
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang Y, Zhu L, Miao Y, Zhu Y, Yue B. Tailored drug delivery platforms: stimulus-responsive core-shell structured nanocarriers. Adv Healthc Mater. 2024;13(1):e2301726. doi:10.1002/adhm.202301726
   PubMed Web of Science ®Google Scholar
• Batool S, Sohail S, Ud Din F, et al. A detailed insight of the tumor targeting using nanocarrier drug delivery system. Drug Deliv. 2023;30(1):2183815. doi:10.1080/10717544.2023.2183815
   PubMed Web of Science ®Google Scholar
• Mu W, Chu Q, Liu Y, Zhang N. A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nanomicro Lett. 2020;12(1):142. doi:10.1007/s40820-020-00482-6
   PubMed Web of Science ®Google Scholar
• Shim MK, Song SK, Jeon SI, Hwang KY, Kim K. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opin Drug Deliv. 2022;19(6):641–652. doi:10.1080/17425247.2022.2081683
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang J, Tian B, Wu Z, Svirskis D, Han J. A NAG-guided nano-delivery system for redox- and pH-triggered intracellularly sequential drug release in cancer cells. Int J Nanomed. 2020;15:841–855. doi:10.2147/IJN.S226249
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang PY, Liu Z, et al. Dual stimuli-responsive micelles for imaging-guided mitochondrion-targeted photothermal/photodynamic/chemo combination therapy-induced immunogenic cell death. Int J Nanomed. 2023;18:4381–4402. doi:10.2147/IJN.S410047
   PubMed Web of Science ®Google Scholar
• Kepp O, Kroemer G. Immunogenic cell stress and death sensitize tumors to immunotherapy. Cells. 2023;12(24):2843. doi:10.3390/cells12242843
   PubMed Web of Science ®Google Scholar
• Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280(1):126–148. doi:10.1111/imr.12574
   PubMed Web of Science ®Google Scholar
• Luan Y, Luan Y, Jiao Y, et al. Broadening horizons: exploring mtDAMPs as a mechanism and potential intervention target in cardiovascular diseases. Aging Dis. 2023;1130. doi:10.14336/AD.2023.1130
   Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi:10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Birmpilis AI, Paschalis A, Mourkakis A, et al. Immunogenic cell death, DAMPs and prothymosin α as a putative anticancer immune response biomarker. Cells. 2022;11(9):1415. doi:10.3390/cells11091415
   PubMed Web of Science ®Google Scholar
• Luo W, Yu Z. Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investig. 2015;2:16. doi:10.3978/j.issn.2306-9759.2015.08.01
   PubMedGoogle Scholar
• Zhang M, Xiao J, Liu J, et al. Calreticulin as a marker and therapeutic target for cancer. Clin Exp Med. 2023;23(5):1393–1404. doi:10.1007/s10238-022-00937-7
   PubMed Web of Science ®Google Scholar
• Politis PK, Charonis AS. Calreticulin in renal fibrosis: a short review. J Cell Mol Med. 2022;26(24):5949–5954. doi:10.1111/jcmm.17627
   PubMed Web of Science ®Google Scholar
• Liu X, Xie P, Hao N, et al. HIF-1-regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation. Proc Natl Acad Sci U S A. 2021;118(44):e2109144118. doi:10.1073/pnas.2109144118
   PubMed Web of Science ®Google Scholar
• Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31(1):5–16. doi:10.1038/s41422-020-0383-9
   PubMed Web of Science ®Google Scholar
• Kielbik M, Szulc-Kielbik I, Klink M. Calreticulin-multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients. Cells. 2021;10(1):130. doi:10.3390/cells10010130
   PubMed Web of Science ®Google Scholar
• Bai X, Li Q, Peng X, et al. P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways. Purinergic Sig. 2023. doi:10.1007/s11302-023-09928-z
   Web of Science ®Google Scholar
• Jiang Y, Lin J, Zheng H, Zhu P. The role of purinergic signaling in heart transplantation. Front Immunol. 2022;13:826943. doi:10.3389/fimmu.2022.826943
   PubMed Web of Science ®Google Scholar
• Kepp O, Bezu L, Yamazaki T, et al. ATP and cancer immunosurveillance. EMBO J. 2021;40(13):e108130. doi:10.15252/embj.2021108130
   PubMed Web of Science ®Google Scholar
• Pavelec CM, Young AP, Luviano HL, et al. Pannexin 1 channels control cardiomyocyte metabolism and neutrophil recruitment during non-ischemic heart failure. Preprint bioRxiv. 2023;573679. doi:10.1101/2023.12.29.573679
   Google Scholar
• Dwyer KM, Kishore BK, Robson SC. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol. 2020;16(9):509–524. doi:10.1038/s41581-020-0304-7
   PubMed Web of Science ®Google Scholar
• Yuan Y, Sun M, Jin Z, Zheng C, Ye H, Weng H. Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney. Eur J Pharmacol. 2023;943:175560. doi:10.1016/j.ejphar.2023.175560
   PubMed Web of Science ®Google Scholar
• Shen X, Li WQ. High-mobility group box 1 protein and its role in severe acute pancreatitis. World J Gastroenterol. 2015;21(5):1424–1435. doi:10.3748/wjg.v21.i5.1424
   PubMed Web of Science ®Google Scholar
• Chen R, Zou J, Kang R, Tang D. The redox protein HMGB1 in cell death and cancer. Antioxid Redox Signal. 2023;2. doi:10.1089/ars.2023.0007
   Google Scholar
• Wang S, Zhang Y. HMGB1 in inflammation and cancer. J Hematol Oncol. 2020;13(1):116. doi:10.1186/s13045-020-00950-x
   PubMed Web of Science ®Google Scholar
• Chen S, Tang W, Yu G, Tang Z, Liu E. CXCL12/CXCR4 axis is involved in the recruitment of NK cells by HMGB1 contributing to persistent airway inflammation and AHR during the late stage of RSV infection. J Microbiol. 2023;61(4):461–469. doi:10.1007/s12275-023-00018-8
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu P, Wen Y, et al. Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases. Mol Cancer. 2023;22(1):95. doi:10.1186/s12943-023-01790-2
   PubMed Web of Science ®Google Scholar
• Hu C, Yang J, Qi Z, et al. Heat shock proteins: biological functions, pathological roles, and therapeutic opportunities. MedComm. 2022;3(3):e161. doi:10.1002/mco2.161
   PubMedGoogle Scholar
• Sakai S, Shichita T. Role of alarmins in poststroke inflammation and neuronal repair. Semin Immunopathol. 2023;45(3):427–435. doi:10.1007/s00281-022-00961-5
   PubMed Web of Science ®Google Scholar
• Bai S, Yang LL, Wang Y, et al. Prodrug-based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death. Small. 2020;16(19):e2000214. doi:10.1002/smll.202000214
   PubMed Web of Science ®Google Scholar
• Workenhe ST, Pol J, Kroemer G. Tumor-intrinsic determinants of immunogenic cell death modalities. Oncoimmunology. 2021;10(1):1893466. doi:10.1080/2162402X.2021.1893466
   PubMed Web of Science ®Google Scholar
• Zhang R, Kang R, Tang D. The STING1 network regulates autophagy and cell death. Signal Transduct Target Ther. 2021;6(1):208. doi:10.1038/s41392-021-00613-4
   PubMed Web of Science ®Google Scholar
• Wang H, Chen Y, Wei R, et al. Synergistic chemoimmunotherapy augmentation via sequential nanocomposite hydrogel-mediated reprogramming of cancer-associated fibroblasts in osteosarcoma. Adv Mater. 2023;9591. doi:10.1002/adma.202309591
   Web of Science ®Google Scholar
• Wang A, Yang X, Li R, et al. Immunomodulator-mediated suppressive tumor immune microenvironment remodeling nanoplatform for enhanced immuno/chemo/photothermal combination therapy of triple negative breast cancer. ACS Appl Mater Interfaces. 2023;15(46):53318–53332. doi:10.1021/acsami.3c14137
   PubMed Web of Science ®Google Scholar
• Duo Y, Chen Z, Li Z, et al. Combination of bacterial-targeted delivery of gold-based AIEgen radiosensitizer for fluorescence-image-guided enhanced radio-immunotherapy against advanced cancer. Bioact Mater. 2023;30:200–213. doi:10.1016/j.bioactmat.2023.05.010
   PubMed Web of Science ®Google Scholar
• Liu YB, Chen XY, Yu BX, et al. Chimeric peptide-engineered self-delivery nanomedicine for photodynamic-triggered breast cancer immunotherapy by macrophage polarization. Small. 2023;94. doi:10.1002/smll.202309994
   Web of Science ®Google Scholar
• Ji S, Li J, Duan X, et al. Targeted enrichment of enzyme-instructed assemblies in cancer cell lysosomes turns immunologically cold tumors hot. Angew Chem Int Ed Engl. 2021;60(52):26994–27004. doi:10.1002/anie.202110512
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–4865. doi:10.1111/jcmm.14356
   PubMed Web of Science ®Google Scholar
• Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol Dordr. 2020;43(6):1203–1214. doi:10.1007/s13402-020-00552-2
   PubMed Web of Science ®Google Scholar
• Chang X, Bian M, Liu L, et al. Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacol Res. 2023;187:106556. doi:10.1016/j.phrs.2022.106556
   PubMed Web of Science ®Google Scholar
• Kaneko K, Acharya CR, Nagata H, et al. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers. J Immunother Cancer. 2022;10(9):e004793. doi:10.1136/jitc-2022-004793
   PubMed Web of Science ®Google Scholar
• Wu Q, Li Z, Zhou X, et al. Photothermal ferrotherapy-induced immunogenic cell death via iron-based ternary chalcogenide nanoparticles against triple-negative breast cancer. Small. 2023;766. doi:10.1002/smll.202306766
   Web of Science ®Google Scholar
• Li T, Gao M, Wu Z, et al. Tantalum-zirconium co-doped metal-organic frameworks sequentially sensitize radio-radiodynamic-immunotherapy for metastatic osteosarcoma. Adv Sci. 2023;10(10):e2206779. doi:10.1002/advs.202206779
   Web of Science ®Google Scholar
• Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7(1):331. doi:10.1038/s41392-022-01136-2
   PubMed Web of Science ®Google Scholar
• Wang R, Kumar P, Reda M, et al. Nanotechnology applications in breast cancer immunotherapy. Small. 2023. doi:10.1002/smll.202308639
   Web of Science ®Google Scholar
• Kim GR, Choi JM. Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells. 2022;45(8):513–521. doi:10.14348/molcells.2022.2056
   PubMed Web of Science ®Google Scholar
• Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44. doi:10.1186/s12964-022-00854-y
   PubMed Web of Science ®Google Scholar
• Chi Z, Lu Y, Yang Y, Li B, Lu P. Transcriptional and epigenetic regulation of PD-1 expression. Cell Mol Life Sci. 2021;78(7):3239–3246. doi:10.1007/s00018-020-03737-y
   PubMed Web of Science ®Google Scholar
• Pang K, Shi ZD, Wei LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat. 2023;66:100907. doi:10.1016/j.drup.2022.100907
   PubMed Web of Science ®Google Scholar
• Pimenta J, Prada J, Pires I, Cotovio M. Programmed cell death-ligand 1 (PD-L1) immunohistochemical expression in equine melanocytic tumors. Animals. 2023;14(1):48. doi:10.3390/ani14010048
   Web of Science ®Google Scholar
• Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2(10):1001–1012. doi:10.1038/s42255-020-00280-9
   PubMedGoogle Scholar
• Chen Y, Zhi S, Ou J, et al. Cancer cell membrane-coated nanoparticle co-loaded with photosensitizer and toll-like receptor 7 agonist for the enhancement of combined tumor immunotherapy. ACS Nano. 2023;17(17):16620–16632. doi:10.1021/acsnano.3c02724
   PubMed Web of Science ®Google Scholar
• Luo C, Chen H, Wu H, Liu Y, Li G, Lun W. Case report: toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis. Front Immunol. 2023;14:1298902. doi:10.3389/fimmu.2023.1298902
   PubMedGoogle Scholar
• Zeng TM, Yang G, Lou C, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun. 2023;14(1):1340. doi:10.1038/s41467-023-37030-w
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international Phase 3 study. Lancet. 2023;402(10408):1133–1146. doi:10.1016/S0140-6736(23)00961-3
   PubMed Web of Science ®Google Scholar
• Ding K, Liu H, Ma J, et al. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter Phase II trial. Haematologica. 2023;108(8):2146–2154. doi:10.3324/haematol.2022.282266
   PubMed Web of Science ®Google Scholar
• Shi Y, Gao L, Tian Y, et al. Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase II study. ESMO Open. 2023;8(6):102194. doi:10.1016/j.esmoop.2023.102194
   PubMed Web of Science ®Google Scholar
• Xia L, Wang J, Wang C, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecol Cancer. 2023;33(12):1861–1868. doi:10.1136/ijgc-2023-004705
   PubMed Web of Science ®Google Scholar
• Markham A. Envafolimab: first approval. Drugs. 2022;82(2):235–240. doi:10.1007/s40265-022-01671-w
   PubMed Web of Science ®Google Scholar
• Keam SJ. Cadonilimab: first approval. Drugs. 2022;82(12):1333–1339. doi:10.1007/s40265-022-01761-9
   PubMed Web of Science ®Google Scholar
• Provencio M, Nadal E, González-Larriba JL, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;389(6):504–513. doi:10.1056/NEJMoa2215530
   PubMed Web of Science ®Google Scholar
• Lim SM, Peters S, Ortega Granados AL, et al. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. Nat Commun. 2023;14(1):7301. doi:10.1038/s41467-023-42900-4
   PubMed Web of Science ®Google Scholar
• Schmid P, Turner NC, Barrios CH, et al. First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast cancer: clinical and biomarker results. Clin Cancer Res. 2023. doi:10.1158/1078-0432.CCR-23-2084
   Web of Science ®Google Scholar
• Johnson ML, Cho BC, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the Phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213–1227. doi:10.1200/JCO.22.00975
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113–2125. doi:10.1056/NEJMoa2210233
   PubMed Web of Science ®Google Scholar
• Guo J, Zou Y, Huang L. Nano delivery of chemotherapeutic ICD inducers for tumor immunotherapy. Small Methods. 2023;7(5):e2201307. doi:10.1002/smtd.202201307
   PubMed Web of Science ®Google Scholar
• Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24. doi:10.1186/s13045-022-01242-2
   PubMed Web of Science ®Google Scholar
• Han X, Li H, Zhou D, Chen Z, Gu Z. Local and targeted delivery of immune checkpoint blockade therapeutics. Acc Chem Res. 2020;53(11):2521–2533. doi:10.1021/acs.accounts.0c00339
   PubMed Web of Science ®Google Scholar
• Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;152(3):357–371. doi:10.1111/imm.12788
   PubMed Web of Science ®Google Scholar
• Verschueren MV, Peters BJ, Bloem LT, et al. Pembrolizumab plus chemotherapy per PD-L1 stratum in patients with metastatic non-small cell lung cancer: real-world effectiveness versus trial efficacy. Clin Lung Cancer. 2023. doi:10.1016/j.cllc.2023.12.011
   PubMedGoogle Scholar
• Li R, Liang H, Li J, et al. Paclitaxel liposome (lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study. BMC Cancer. 2024;24(1):107. doi:10.1186/s12885-024-11860-3
   PubMed Web of Science ®Google Scholar
• Luo S, Lv Z, Yang Q, Chang R, Wu J. Research progress on stimulus-responsive polymer nanocarriers for cancer treatment. Pharmaceutics. 2023;15(7):1928. doi:10.3390/pharmaceutics15071928
   PubMed Web of Science ®Google Scholar
• Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205–227. doi:10.1080/17425247.2021.1828339
   PubMed Web of Science ®Google Scholar
• Yan Z, Liu Y, Zhao L, et al. In situ stimulus-responsive self-assembled nanomaterials for drug delivery and disease treatment. Mater Horiz. 2023;10(9):3197–3217. doi:10.1039/d3mh00592e
   PubMed Web of Science ®Google Scholar
• Karimi M, Ghasemi A, Sahandi Zangabad P, et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457–1501. doi:10.1039/c5cs00798d
   PubMed Web of Science ®Google Scholar
• Kaushik N, Borkar SB, Nandanwar SK, Panda PK, Choi EH, Kaushik NK. Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnol. 2022;20(1):152. doi:10.1186/s12951-022-01364-2
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen L, Ma Y, et al. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. J Nanobiotechnol. 2021;19(1):243. doi:10.1186/s12951-021-00975-5
   PubMed Web of Science ®Google Scholar
• Zhang X, Yi C, Zhang L, et al. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for “cold” tumor immunotherapy. Acta Biomater. 2023;159:338–352. doi:10.1016/j.actbio.2023.01.023
   PubMed Web of Science ®Google Scholar
• Tian Y, Younis MR, Zhao Y, et al. Precision delivery of dual immune inhibitors loaded nanomodulator to reverse immune suppression for combinational photothermal-immunotherapy. Small. 2023;19(21):e2206441. doi:10.1002/smll.202206441
   PubMed Web of Science ®Google Scholar
• Zheng RR, Zhao LP, Yang N, et al. Cascade immune activation of self-delivery biomedicine for photodynamic immunotherapy against metastatic tumor. Small. 2023;19(3):e2205694. doi:10.1002/smll.202205694
   PubMed Web of Science ®Google Scholar
• Liu H, Hu Y, Sun Y, et al. Co-delivery of bee venom melittin and a photosensitizer with an organic-inorganic hybrid nanocarrier for photodynamic therapy and immunotherapy. ACS Nano. 2019;13(11):12638–12652. doi:10.1021/acsnano.9b04181
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhu T, Zeng Q, Tan Q, Jiang G, Huang X. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Acta Biomater. 2023;157:451–466. doi:10.1016/j.actbio.2022.11.043
   PubMed Web of Science ®Google Scholar
• Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2022;280:121312. doi:10.1016/j.biomaterials.2021.121312
   PubMed Web of Science ®Google Scholar
• Yu Q, Tang X, Zhao W, et al. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles. Acta Biomater. 2021;133:244–256. doi:10.1016/j.actbio.2021.05.002
   PubMed Web of Science ®Google Scholar
• Liu X, Zheng J, Sun W, et al. Ferrimagnetic vortex nanoring-mediated mild magnetic hyperthermia imparts potent immunological effect for treating cancer metastasis. ACS Nano. 2019;13(8):8811–8825. doi:10.1021/acsnano.9b01979
   PubMed Web of Science ®Google Scholar
• Pan J, Hu P, Guo Y, et al. Combined magnetic hyperthermia and immune therapy for primary and metastatic tumor treatments. ACS Nano. 2020;14(1):1033–1044. doi:10.1021/acsnano.9b08550
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Q, Hinojosa DT, et al. Multifunctional magnetic nanoclusters can induce immunogenic cell death and suppress tumor recurrence and metastasis. ACS Nano. 2022;16(11):18538–18554. doi:10.1021/acsnano.2c06776
   PubMed Web of Science ®Google Scholar
• Zhang Q, Shi D, Guo M, Zhao H, Zhao Y, Yang X. Radiofrequency-activated pyroptosis of bi-valent gold nanocluster for cancer immunotherapy. ACS Nano. 2023;17(1):515–529. doi:10.1021/acsnano.2c09242
   PubMed Web of Science ®Google Scholar
• Wang Z, Little N, Chen J, et al. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat Nanotechnol. 2021;16(10):1130–1140. doi:10.1038/s41565-021-00950-z
   PubMed Web of Science ®Google Scholar
• Moon Y, Shim MK, Choi J, et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022;12(5):1999–2014. doi:10.7150/thno.69119
   PubMed Web of Science ®Google Scholar
• Bai X, Zhou Y, Yokota Y, et al. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. J Exp Clin Cancer Res. 2022;41(1):132. doi:10.1186/s13046-022-02307-3
   PubMed Web of Science ®Google Scholar
• Xia GQ, Lei TR, Yu TB, Zhou PH. Nanocarrier-based activation of necroptotic cell death potentiates cancer immunotherapy. Nanoscale. 2021;13(2):1220–1230. doi:10.1039/d0nr05832g
   PubMed Web of Science ®Google Scholar
• Wang C, Shi X, Song H, et al. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Biomaterials. 2021;268:120579. doi:10.1016/j.biomaterials.2020.120579
   PubMed Web of Science ®Google Scholar
• Zhu W, Bai Y, Zhang N, et al. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer. J Mater Chem B. 2021;9(20):4201–4210. doi:10.1039/d1tb00537e
   PubMed Web of Science ®Google Scholar
• Jiang M, Chen W, Yu W, et al. Sequentially pH-responsive drug-delivery nanosystem for tumor immunogenic cell death and cooperating with immune checkpoint blockade for efficient cancer chemoimmunotherapy. ACS Appl Mater Interfaces. 2021;13(37):43963–43974. doi:10.1021/acsami.1c10643
   PubMed Web of Science ®Google Scholar
• Wu J, Chen J, Feng Y, et al. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles. Sci Adv. 2020;6(40):eabc7828. doi:10.1126/sciadv.abc7828
   PubMed Web of Science ®Google Scholar
• Ge YX, Zhang TW, Zhou L, et al. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework. Biomaterials. 2022;282:121407. doi:10.1016/j.biomaterials.2022.121407
   PubMed Web of Science ®Google Scholar
• Xu J, Qiu W, Liang M, et al. Dual-stimulus phototherapeutic nanogel for triggering pyroptosis to promote cancer immunotherapy. J Control Release. 2023;358:219–231. doi:10.1016/j.jconrel.2023.04.030
   PubMed Web of Science ®Google Scholar
• Xie L, Wang G, Sang W, et al. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy. Biomaterials. 2021;269:120638. doi:10.1016/j.biomaterials.2020.120638
   PubMed Web of Science ®Google Scholar
• Jeong SD, Jung BK, Ahn HM, et al. Immunogenic cell death inducing fluorinated mitochondria-disrupting helical polypeptide synergizes with PD-L1 immune checkpoint blockade. Adv Sci. 2021;8(7):2001308. doi:10.1002/advs.202001308
   Web of Science ®Google Scholar
• Wan WJ, Huang G, Wang Y. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. Acta Biomater. 2021;136:473–484. doi:10.1016/j.actbio.2021.09.040
   PubMed Web of Science ®Google Scholar
• Jia L, Pang M, Fan M, et al. A pH-responsive Pickering nanoemulsion for specified spatial delivery of immune checkpoint inhibitor and chemotherapy agent to tumors. Theranostics. 2020;10(22):9956–9969. doi:10.7150/thno.46089
   PubMed Web of Science ®Google Scholar
• Hou G, Qian J, Guo M, et al. Hydrazide-manganese coordinated multifunctional nanoplatform for potentiating immunotherapy in hepatocellular carcinoma. J Colloid Interface Sci. 2022;628(Pt B):968–983. doi:10.1016/j.jcis.2022.08.091
   PubMedGoogle Scholar
• Xu Y, Guo Y, Zhang C, et al. Fibronectin-coated metal-phenolic networks for cooperative tumor chemo-/chemodynamic/Immune therapy via enhanced ferroptosis-mediated immunogenic cell death. ACS Nano. 2022;16(1):984–996. doi:10.1021/acsnano.1c08585
   PubMed Web of Science ®Google Scholar
• Wang M, Chang M, Li C, et al. Tumor-microenvironment-activated reactive oxygen species amplifier for enzymatic cascade cancer starvation/chemodynamic/immunotherapy. Adv Mater. 2022;34(4):e2106010. doi:10.1002/adma.202106010
   PubMed Web of Science ®Google Scholar
• Ding M, Fan Y, Lv Y. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy. Acta Biomater. 2022;149:334–346. doi:10.1016/j.actbio.2022.06.041
   PubMed Web of Science ®Google Scholar
• Lu YF, Zhou JP, Zhou QM. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma. J Nanobiotechnol. 2022;20(1):351. doi:10.1186/s12951-022-01565-9
   PubMed Web of Science ®Google Scholar
• Yue J, Mei Q, Wang P, Miao P, Dong WF, Li L. Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy. J Nanobiotechnol. 2022;20(1):181. doi:10.1186/s12951-022-01388-8
   PubMed Web of Science ®Google Scholar
• Su Z, Xiao Z, Wang Y. Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-Sensitive micelles for enhanced tumor chemoimmunotherapy. Small. 2020;16(7):e1906832. doi:10.1002/smll.201906832
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen XG, Yang PP, Qiao ZY, Wang H. Tumor microenvironmental pH and enzyme dual responsive polymer-Liposomes for synergistic treatment of cancer immuno-chemotherapy. Biomacromolecules. 2019;20(2):882–892. doi:10.1021/acs.biomac.8b01510
   PubMed Web of Science ®Google Scholar
• Dahri M, Beheshtizadeh N, Seyedpour N, et al. Biomaterial-based delivery platforms for transdermal immunotherapy. Biomed Pharmacother. 2023;165:115048. doi:10.1016/j.biopha.2023.115048
   PubMed Web of Science ®Google Scholar
• Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. doi:10.3389/fimmu.2023.1212476
   PubMedGoogle Scholar
• Li L, Yang Z, Chen X. Recent advances in stimuli-responsive platforms for cancer immunotherapy. Acc Chem Res. 2020;53(10):2044–2054. doi:10.1021/acs.accounts.0c00334
   PubMed Web of Science ®Google Scholar
• Vincent MP, Navidzadeh JO, Bobbala S, Scott EA. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell. 2022;40(3):255–276. doi:10.1016/j.ccell.2022.01.006
   PubMed Web of Science ®Google Scholar
• Shin Y, Husni P, Kang K. Recent advances in pH- or/and photo-responsive nanovehicles. pharmaceutics. 2021;13(5):725. doi:10.3390/pharmaceutics13050725
   PubMed Web of Science ®Google Scholar
• Chauhan M, Basu SM, Qasim M, Giri J. Polypropylene sulphide coating on magnetic nanoparticles as a novel platform for excellent biocompatible, stimuli-responsive smart magnetic nanocarriers for cancer therapeutics. Nanoscale. 2023;15(16):7384–7402. doi:10.1039/d2nr05218k
   PubMed Web of Science ®Google Scholar
• Yusefi M, Shameli K, Jahangirian H. How magnetic composites are effective anticancer therapeutics? A comprehensive review of the literature. Int J Nanomed. 2023;18:3535–3575. doi:10.2147/IJN.S375964
   PubMed Web of Science ®Google Scholar
• Zhang K, Qi C, Cai K. Manganese-based tumor immunotherapy. Adv Mater. 2023;35(19):e2205409. doi:10.1002/adma.202205409
   PubMed Web of Science ®Google Scholar
• Eslami P, Albino M, Scavone F. Smart magnetic nanocarriers for multi-stimuli on-demand drug delivery. Nanomaterials. 2022;12(3):303. doi:10.3390/nano12030303
   Web of Science ®Google Scholar
• Ge J, Yang N, Yang Y. The combination of eddy thermal effect of biodegradable magnesium with immune checkpoint blockade shows enhanced efficacy against osteosarcoma. Bioact Mater. 2023;25:73–85. doi:10.1016/j.bioactmat.2023.01.008
   PubMed Web of Science ®Google Scholar
• Kapalatiya H, Madav Y, Tambe VS, Wairkar S. Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview. Drug Deliv Transl Res. 2022;12(6):1293–1305. doi:10.1007/s13346-021-01020-6
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhu L, Liu M, He L, Xu H, Jia J. Enzyme-responsive lignin nanocarriers for triggered delivery of abamectin to control plant root-knot nematodes (Meloidogyne incognita). J Agric Food Chem. 2023;71(8):3790–3799. doi:10.1021/acs.jafc.2c07466
   PubMed Web of Science ®Google Scholar
• Jia N, Gao Y, Li M. Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms. Signal Transduct Target Ther. 2023;8(1):280. doi:10.1038/s41392-023-01499-0
   PubMed Web of Science ®Google Scholar
• Ding H, Tan P, Fu S. Preparation and application of pH-responsive drug delivery systems. J Control Release. 2022;348:206–238. doi:10.1016/j.jconrel.2022.05.056
   PubMed Web of Science ®Google Scholar
• Lee CG, Kwon TH. Controlling morphologies of redox-responsive polymeric nanocarriers for a smart drug delivery system. Chemistry. 2023;29(34):e202300594. doi:10.1002/chem.202300594
   PubMed Web of Science ®Google Scholar
• Mollazadeh S, Mackiewicz M, Yazdimamaghani M. Recent advances in the redox-responsive drug delivery nanoplatforms: a chemical structure and physical property perspective. Mater Sci Eng C Mater Biol Appl. 2021;118:111536. doi:10.1016/j.msec.2020.111536
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhu D, Tong Z, et al. Influence of surface ligand density and particle size on the penetration of the blood-brain barrier by porous silicon nanoparticles. Pharmaceutics. 2023;15(9):2271. doi:10.3390/pharmaceutics15092271
   PubMed Web of Science ®Google Scholar
• Nezhadi S, Dorkoosh FA. Co-delivery systems: hope for clinical application? Drug Deliv Transl Res. 2022;12(6):1339–1354. doi:10.1007/s13346-021-01041-1
   PubMed Web of Science ®Google Scholar
• Chen D, Liu X, Lu X, Tian J. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol. 2023;14:1111991. doi:10.3389/fphar.2023.1111991
   PubMed Web of Science ®Google Scholar
• Al Bostami RD, Abuwatfa WH, Husseini GA. Recent advances in nanoparticle-based co-delivery systems for cancer therapy. Nanomaterials. 2022;12(15):2672. doi:10.3390/nano12152672
   Web of Science ®Google Scholar
• Liang Y, Liu ZY, Wang PY, Li YJ, Wang RR, Xie SY. Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant. J Control Release. 2021;336:396–409. doi:10.1016/j.jconrel.2021.06.034
   PubMed Web of Science ®Google Scholar
• Qi J, Jin F, You Y, et al. Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles. Nat Commun. 2021;12(1):4755. doi:10.1038/s41467-021-24902-2
   PubMed Web of Science ®Google Scholar
• DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785–797. doi:10.1038/s41577-021-00541-y
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-0
   PubMed Web of Science ®Google Scholar